By controlling the BCL2, BAX, cleaved caspase-3, MMP-2, and MMP-9 pathways, the results showed the potential of brusatol delivered by plCSA-modified NPs as a chemotherapeutic agent for the targeted therapy of tumours. Here, BCL2 is linked to neoplasm.